ClinicalTrials.Veeva

Menu

Clinical Trial of Bile Etiology ,Proteomics and Metabonomics of Malignant Biliary Obstruction (MBO-IR)

T

Tianjin Medical University

Status

Unknown

Conditions

Malignant Biliary Obstruction

Study type

Observational

Funder types

Other

Identifiers

NCT01073514
TMU-CIH-IR-001
ChiCTR-ONC-00000752 (Registry Identifier)

Details and patient eligibility

About

To investigate bile culture and susceptibility test in patients with malignant biliary obstruction (MBO) or relation between bile, portal vein or vein culture and biliary infection. Also to get the information of bile metabonomics to find potential tumor marker .Culture of the organism is recognized as the "gold standard" for diagnosis of infection. Our research may be one of the first research on culture and susceptibility test in patients with MBO. The results of the trial research will be benefit to experiential therapy of MBO with biliary infection and diagnosis of MBO.

Full description

We will obtain bile sample for culture and susceptibility ,proteomics metabonomics test after PTBD. Also get the blood and urine samples.

Enrollment

300 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Those with MBO who can receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Exclusion criteria

  • Those with MBO who cannot receive Percutaneous Transhepatic Biliary Drainage(PTBD)

Trial contacts and locations

1

Loading...

Central trial contact

YU HAI PENG, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems